|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004153,
umls-concept:C0008976,
umls-concept:C0011860,
umls-concept:C0031638,
umls-concept:C0034656,
umls-concept:C0043799,
umls-concept:C0055729,
umls-concept:C0199176,
umls-concept:C0205263,
umls-concept:C0332307,
umls-concept:C0401925,
umls-concept:C0577631,
umls-concept:C0681850,
umls-concept:C0684321,
umls-concept:C1274040,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2603343,
umls-concept:C2697811
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2010-6-15
|
|
pubmed:abstractText |
Antiplatelet drugs are effective in preventing recurrence of atherosclerosis in type 2 diabetic patients. However, the efficacy and usefulness of 2 different antiplatelet drugs, aspirin and cilostazol, in the progression of carotid intima-media thickening are unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
121
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2584-91
|
|
pubmed:meshHeading |
pubmed-meshheading:20516379-Aged,
pubmed-meshheading:20516379-Atherosclerosis,
pubmed-meshheading:20516379-Carotid Artery Diseases,
pubmed-meshheading:20516379-Diabetes Mellitus, Type 2,
pubmed-meshheading:20516379-Female,
pubmed-meshheading:20516379-Humans,
pubmed-meshheading:20516379-Male,
pubmed-meshheading:20516379-Middle Aged,
pubmed-meshheading:20516379-Phosphodiesterase Inhibitors,
pubmed-meshheading:20516379-Prospective Studies,
pubmed-meshheading:20516379-Tetrazoles
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
|
|
pubmed:affiliation |
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
